A groundbreaking analysis of thousands of high-impact clinical trials has exposed a stark reality: Africa, home to nearly 20% of the world's population and bearing a quarter of the global disease burden, remains strikingly absent from the research shaping modern medicine. Despite this, South Africa stands out as the continental powerhouse, hosting over 62% of all trials conducted on African soil. This disparity not only undermines the validity of global health evidence but also highlights South Africa's universities as pivotal hubs driving research excellence amid broader continental challenges.

The study, reviewing 2,472 randomized controlled trials published in top journals like The Lancet, NEJM, and JACC from 2019 to 2024, found that only 3.9% of trials in leading general medical journals were run exclusively in Africa. In cardiovascular research—a field where Africa faces a surging crisis—just 0.6% were Africa-only. Multicontinental trials including African sites numbered more, but local scientists led a mere 3.6% of them, often reducing the continent to mere recruitment grounds rather than intellectual partners.

South Africa's Dominant Position in Continental Research

South Africa's clinical trials landscape dwarfs the rest of Africa. It accounts for more than 62% of continent-wide activity, with southern Africa overall leading regional contributions. This is no accident; decades of investment have built robust infrastructure, from experienced clinical research units to streamlined ethics reviews. In oncology trials registered via WHO-ICTRP, Egypt, Algeria, and South Africa topped contributions, but SA's share remains outsized.

• South Africa: 62%+ of African trials
• Central Africa: <3%, despite 180 million residents
• North Africa (e.g., Egypt): Notable but secondary
• Sub-Saharan non-SA: Fragmented and minimal

This concentration raises equity concerns but also positions SA as a model for expansion. For full study details, see the JACC publication.

Key South African Universities Powering Clinical Trials

South African higher education institutions are at the forefront, leveraging world-class facilities and international partnerships. The University of Cape Town's Clinical Trials Unit (UCTCTU) excels in HIV/AIDS prevention and treatment, supported by NIH funding. Stellenbosch University's Clinical Trials Unit (SUN-CTU) focuses on TB and HIV, collaborating with global networks like DAIDS. The University of the Witwatersrand (Wits) leads in infectious diseases and non-communicable trials, while the University of Pretoria contributes to vaccine and oncology research.

These centers not only host trials but train the next generation of researchers, fostering a pipeline of expertise. Wits, for instance, runs advanced TB trials through its Desmond Tutu TB Centre partnership.

Why South Africa Excels: Infrastructure and Historical Momentum

South Africa's edge stems from post-apartheid investments in research governance, academic hubs, and sponsor ties. Unlike many neighbors, it boasts Good Clinical Practice (GCP)-compliant sites, diverse patient pools, and efficient regulatory bodies like SAHPRA. English as a working language aids global collaboration. Universities like UCT and Stellenbosch have NIH-funded units, enabling high retention rates over 85-96%.

Contrast this with Central Africa's scant output: limited funding, fragile institutions, and political instability. SA's market is projected to grow from USD 366 million in 2025 to USD 690 million by 2033, underscoring its appeal.

Health Impacts of Exclusion: From Evidence Gaps to Risky Extrapolation

Excluding Africans from trials erodes evidence validity. Drugs tested elsewhere may falter due to genetic, dietary, and environmental differences. ACE inhibitors, for example, pose 3-4x higher risks in African-descent populations. Africa's NCDs now cause 38% of deaths, yet 76% of local trials target infections, ignoring strokes, diabetes, and cancers.

In CV trials, underrepresentation hampers precision medicine. SA's dominance helps locally but leaves the continent vulnerable, perpetuating a cycle where global guidelines don't fit African realities.

Photo by James Wiseman on Unsplash

Barriers Beyond South Africa: Funding, Ethics, and Mistrust

Other African nations face multifaceted hurdles:

• Infrastructure deficits: Few GCP sites, poor labs.
• Funding bias: Donors prioritize infections over NCDs.
• Regulatory delays: Ethics committees overburdened.
• Historical mistrust: Colonial exploitation echoes in hesitancy.
• Workforce shortages: Few trained investigators.

Central Africa's <3% share exemplifies this; solutions demand pan-African investment.

Case Studies: SA-Led Trials Setting Benchmarks

UCTCTU's HIV prevention trials have influenced global PrEP strategies. SUN-CTU's TB studies via PanACEA advance shorter regimens. Wits' HVTN trials test long-acting PrEP, with high retention. These exemplify SA's capacity to deliver rigorous data, often outperforming global averages.

For more on oncology trends, review the WHO-ICTRP analysis.

Building Pan-African Capacity: SA Universities' Role

SA institutions mentor continent-wide via EDCTP, AMERA. UCT and Stellenbosch train investigators from East/West Africa. Initiatives like Alliance for Medical Research in Africa equip locals, aiming for leadership beyond recruitment.

Pathways Forward: Investments and Policy Shifts

Solutions include:

• Ring-fenced African-led funding.
• Regional networks like ACRN.
• Journal diversity mandates.
• Harmonized ethics via African Medicines Agency.
• SA-style training scaled continentally.

Pharma urged to invest; Africa's networks show 80%+ consent rates. See Gavi's insights on expanding trials.

Career Opportunities in SA's Research Ecosystem

SA universities offer booming roles in clinical research: coordinators at UCT, biostatisticians at Wits, ethicists at Stellenbosch. Demand surges with market growth, ideal for postdocs and lecturers. Explore positions via specialized job boards.

Photo by James Wiseman on Unsplash

A Call for Equitable Global Research

South Africa's leadership is a beacon, but true progress demands continent-wide upliftment. By bolstering universities beyond borders, Africa can claim its place in evidence generation, ensuring treatments fit its people. SA's model—rooted in strong higher ed—paves the way.